Tuoxin Unit Receives Drug Approval for Safinamide Mesylate API

Stock News

Sep 22

Tuoxin Pharmaceutical Group Co., Ltd. (301089.SZ) announced that its wholly-owned subsidiary, Xinxiang Pharmaceutical Co., Ltd., has received the"Chemical Drug API Listing Approval Notice"issued by the National Medical Products Administration for the safinamide mesylate active pharmaceutical ingredient (API).

Safinamide mesylate is a selective inhibitor of monoamine oxidase B (MAO-B), primarily used in patients with mid-to-late-stage Parkinson's disease. Its core mechanism involves inhibiting MAO-B and blocking voltage-dependent sodium channels to regulate glutamate release.

The approved indication is for the treatment of adult patients with idiopathic Parkinson's disease (PD), as an add-on therapy to a stable dose of levodopa (L-dopa), either alone or in combination with other PD treatments, specifically for patients experiencing mid-to-late-stage motor fluctuations.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://sg1.tigeractivity.com/news/1167522166"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1167522166\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1167522166?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-09-22 16:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1167522166","market":"nz","top_or_hot":-1,"title":"Tuoxin Unit Receives Drug Approval for Safinamide Mesylate API","media":"Stock News","content":"<p>Tuoxin Pharmaceutical Group Co., Ltd. (301089.SZ) announced that its wholly-owned subsidiary, Xinxiang Pharmaceutical Co., Ltd., has received the\"Chemical Drug API Listing Approval Notice\"issued by the National Medical Products Administration for the safinamide mesylate active pharmaceutical ingredient (API).<br><br>Safinamide mesylate is a selective inhibitor of monoamine oxidase B (MAO-B), primarily used in patients with mid-to-late-stage Parkinson's disease. Its core mechanism involves inhibiting MAO-B and blocking voltage-dependent sodium channels to regulate glutamate release.<br><br>The approved indication is for the treatment of adult patients with idiopathic Parkinson's disease (PD), as an add-on therapy to a stable dose of levodopa (L-dopa), either alone or in combination with other PD treatments, specifically for patients experiencing mid-to-late-stage motor fluctuations.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Tuoxin Unit Receives Drug Approval for Safinamide Mesylate API</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTuoxin Unit Receives Drug Approval for Safinamide Mesylate API\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-09-22 16:30</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Tuoxin Pharmaceutical Group Co., Ltd. (301089.SZ) announced that its wholly-owned subsidiary, Xinxiang Pharmaceutical Co., Ltd., has received the\"Chemical Drug API Listing Approval Notice\"issued by the National Medical Products Administration for the safinamide mesylate active pharmaceutical ingredient (API).<br><br>Safinamide mesylate is a selective inhibitor of monoamine oxidase B (MAO-B), primarily used in patients with mid-to-late-stage Parkinson's disease. Its core mechanism involves inhibiting MAO-B and blocking voltage-dependent sodium channels to regulate glutamate release.<br><br>The approved indication is for the treatment of adult patients with idiopathic Parkinson's disease (PD), as an add-on therapy to a stable dose of levodopa (L-dopa), either alone or in combination with other PD treatments, specifically for patients experiencing mid-to-late-stage motor fluctuations.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0239","symbol_name":"医药制造","start_time":0,"source_url":"","article_id":"1167522166","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1167522166","pubTimestamp":1790065830,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Tuoxin Pharmaceutical Group Co., Ltd. (301089.SZ) announced that its wholly-owned subsidiary, Xinxiang Pharmaceutical Co., Ltd., has received the\"Chemical Drug API Listing Approval Notice\"issued by...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"301089":"拓新药业","BK0239":"医药制造","IPOS":"Renaissance International IPO ETF"},"translate_title":"拓新单位获甲磺酸沙非酰胺原料药批件","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"301089":1,"IPOS":1},"content_text":"Tuoxin Pharmaceutical Group Co., Ltd. (301089.SZ) announced that its wholly-owned subsidiary, Xinxiang Pharmaceutical Co., Ltd., has received the\"Chemical Drug API Listing Approval Notice\"issued by the National Medical Products Administration for the safinamide mesylate active pharmaceutical ingredient (API).Safinamide mesylate is a selective inhibitor of monoamine oxidase B (MAO-B), primarily used in patients with mid-to-late-stage Parkinson's disease. Its core mechanism involves inhibiting MAO-B and blocking voltage-dependent sodium channels to regulate glutamate release.The approved indication is for the treatment of adult patients with idiopathic Parkinson's disease (PD), as an add-on therapy to a stable dose of levodopa (L-dopa), either alone or in combination with other PD treatments, specifically for patients experiencing mid-to-late-stage motor fluctuations.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}